Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3980 results
Zogenix begins dosing in Phase Ib Relday multi-dose clinical trial to treat schizophrenia
By PBR Staff Writer
US-based pharmaceutical firm Zogenix has started dosing patients in its multi-dose Phase Ib clinical trial of Relday, a proprietary, long-acting, subcutaneously injected formulation of risperidone being investigated to treat schizophrenia.
Drug Research > Drug Discovery & Development > News
Mast Therapeutics to develop vepoloxamer to treat chronic heart failure
By PBR Staff Writer
US-based biopharmaceutical firm Mast Therapeutics is planning to develop vepoloxamer (MST-188) to treat patients with chronic heart failure.
Drug Research > Drug Discovery & Development > News
Lilly partners with China's Innovent for new oncology therapies
By PBR Staff Writer
Eli Lilly and Company and China-based biopharmaceutical firm Innovent Biologics have collaborated to create possible new treatment options for cancer patients in China and around the world.
Drug Research > Drug Discovery & Development > News
AbbVie enters into license deal with C2N Diagnostics for Alzheimer's disease therapy
By PBR Staff Writer
US-based AbbVie and C2N Diagnostics, a protein diagnostic and therapeutic discovery firm, have collaborated for the development and commercialization of a portfolio of anti-tau antibodies to treat Alzheimer's disease (AD) and other neurological disorders.
Drug Research > Drug Discovery & Development > News
Lilly, Hanmi to develop BTK inhibitor to treat autoimmune diseases
By PBR Staff Writer
Eli Lilly and Company has entered into an exclusive license and collaboration agreement with Hanmi Pharmaceutical to develop and commercialize the latter's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, to treat autoimmune and other diseases.
Drug Research > Drug Discovery & Development > News
Amgen reports positive results from OSLER-1 and OSLER-2 trials of Repatha
By PBR Staff Writer
Amgen has reported positive one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase II (OSLER-1) and Phase III (OSLER-2) open-label extension trials of Repatha (evolocumab).
Drug Research > Drug Discovery & Development > News
Sanofi and Regeneron report 18-month results of ODYSSEY long term trial of Praluent
By PBR Staff Writer
Sanofi and Regeneron Pharmaceuticals have reported positive 18-month results of a Phase III ODYSSEY long term trial of Praluent (alirocumab), an investigational therapy, in patients with hypercholesterolemia.
Drug Research > Drug Discovery & Development > News
Evotec, Second Genome to discover new treatment for microbiome-mediated diseases
By PBR Staff Writer
German drug discovery firm Evotec and US-based biotechnology company Second Genome have entered into a partnership for small molecule-based discovery and development activities to treat microbiome-mediated diseases.
Drug Research > Drug Discovery & Development > News
EMD Serono amends deal with Opexa for multiple sclerosis drug Tcelna
By PBR Staff Writer
Merck subsidiary EMD Serono has made changes to its agreement with Opexa Therapeutics to develop and commercialize its investigational compound Tcelna (imilecleucel-T) for the treatment of multiple sclerosis.
Drug Research > Drug Discovery & Development > News
Korean biotech firm G-treeBNT obtains funding to develop RGN-259/GBT-201 in US
By PBR Staff Writer
RegeneRx Biopharmaceuticals' joint venture partner and licensee G-treeBNT is set to receive $7.28m from the Korean Government and Venture Fund to expand development of its product candidate, RGN-259 (GBT-201), in the US.
Drug Research > Drug Discovery & Development > News
Sandoz receives FDA approval for Zarxio
Generic pharmaceutical company Sandoz’s Zarxio has received an US Food and Drug Administration (FDA) approval for all indications included in the reference product's label.
Drug Research > Drug Discovery & Development > News
UK’s NICE draft guidance recommends apixaban for blood clots
By PBR Staff Writer
The National Institute for Health and Care Excellence (NICE) in the UK has published a new draft guidance which recommends apixaban (Eliquis) as an option for treating and preventing potentially fatal blood clots.
Drug Research > Drug Discovery & Development > News
TG Therapeutics to develop Checkpoint’s antibodies in hematological malignancies
By PBR Staff Writer
TG Therapeutics, Inc. will develop and commercialise Checkpoint Therapeutics’ fully human anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies, as part of an agreement signed between the two companies.
Drug Research > Drug Discovery & Development > News
BioLineRx seeks German approval to begin Phase IIb trial of leukemia drug candidate BL-8040
By PBR Staff Writer
Israeli biopharmaceutical firm BioLineRx has submitted regulatory applications to the German Federal Institute for Drugs and Medical Devices (BfArM) seeking approval to begin a Phase IIb trial of its clinical-stage drug candidate BL-8040 as a new consolidation treatment for acute myeloid leukemia (AML).
Drug Research > Drug Discovery & Development > News
Alizé Pharma begins Phase II trial of AZP-531 to treat Prader-Willi syndrome
By PBR Staff Writer
France-based Alizé Pharma has started a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, to treat patients with Prader-Willi syndrome, a rare genetic metabolic syndrome.
Drug Research > Drug Discovery & Development > News
91-105 of 3980 results